Major depressive disorder (MDD) significantly impairs adolescents' development, with increasing rates of treatment resistance and suicide risk. Ketamine has emerged as a promising, rapid-acting antidepressant in adults, but its efficacy and safety in adolescents remain unclear. This systematic review and meta-analysis aimed to evaluate short-term outcomes of ketamine administration in youth...
This study evaluated the effectiveness of mindfulness-based interventions (MBIs) in managing comorbid depression and diabetes by assessing their efficacy in reducing depressive symptoms and improving glycemic control, while addressing inconsistencies in existing research. A systematic review and meta-analysis were conducted of 17 randomized controlled trials published between 2013 and 2024 and...
To explore the therapeutic effect of mindfulness-based stress reduction in patients with post-stroke mild depression. A total of 80 patients with mild depression after stroke received by our hospital from January 2023 to December 2023 were selected as the study subjects. Randomly divide the patients into two groups: 40 in the control group and 40 in the combination group. The control group...
Adolescent mental health problems have become a public health issue of social concern in re-cent years. Compared with traditional psychological intervention methods, mindfulness meditation, as a flexible and non-invasive intervention method, has shown its potential and has gradually become a research hotspot, providing a fresh viewpoint for mental health education and practice. This article...
This study aimed to evaluate the effectiveness of a short video app-guided mindfulness meditation intervention in improving psychological flexibility and self-compassion and reducing rumination and depressive symptoms among failed entrepreneurs. A randomized controlled trial was conducted with 100 recently failed entrepreneurs (aged 25-55), who were randomly assigned to either an intervention...
Mindfulness-Based Cognitive Therapy (MBCT) reduces depression relapse, yet graduates have expressed a need for structured guidance post-program to maintain mindfulness practice and sustain benefits. To address this, we created MBCT for Depression-Taking it Further (MBCT-D-TiF). To refine and pilot test feasibility and acceptability of MBCT-D-TiF. We collected qualitative focus group data to...
Major depressive disorder (MDD) presents a significant global health challenge, characterized by a high prevalence and significant impact on quality of life. Traditional antidepressants fall short in terms of efficacy and onset speed, up to 60% of patients. This review delves into the new and emerging pharmacologic treatments for MDD, focusing on their mechanisms of action, clinical...
Clinical and preclinical studies increasingly support the antidepressant potential of several anesthetic agents, including ketamine, propofol, nitrous oxide (N2O), sevoflurane, and isoflurane. Their therapeutic effects appear to arise from the regulation of multiple interconnected systems: modulation of glutamatergic and GABAergic signaling, interaction with monoaminergic neurotransmitters...
If available in one's practice area, augmenting current medication therapy with esketamine results in greater rates of remission for treatment resistant depression as compared with quetiapine1.
Intranasal Esketamine is an effective rapid-acting antidepressant currently used to treat treatment-resistant depression. Artificial intelligence is another emerging tool in medicine, but little is known about the effectiveness of combining these innovations in psychiatry. This case report presents the outcome of a 37-year-old patient who received intranasal Esketamine treatment (84 mg) and...